American Peptide Company Announces New Total Peptide Management Program
American Peptide Company, Inc. recently announced its new Total Peptide Management program to help the pharmaceutical and life sciences industries bring new and innovative drugs to market faster. As the first of its kind, Total Peptide Management offers a broad portfolio of peptides, value-added services, and expert consultation to support customer needs as their drug products move from discovery to development and commercialization.
The program is a customized service platform, which comprises a set of comprehensive services, including process development; scale-up production; analytical and process validation; stability studies; Chemistry, Manufacturing, and Controls (CMC); Drug Master Files (DMF) and regulatory support. This platform complements the company's suite of advanced peptides to provide customers with efficient, high-quality and cost-effective peptide management solutions.
The Total Peptide Management program leverages the experience and expertise of American Peptide Company's leadership team to help customers properly select peptides and follow the correct procedures and compliance guidelines to streamline the drug development and manufacture process.
Additionally, the program facilitates greater adherence to manufacturing standards and protocols at the company's state-of-the-art manufacturing facilities. It mandates application of GMP practices to non-GMP applications in the early phases of drug development to provide drug researchers with manufacturing processes that can be scaled up efficiently.
As part of the program, the company provides innovative peptides in a timely and cost-effective manner to drug manufacturers. The high-quality of these peptides helps manufacturers realize improved consistency, with higher yields and reliable product quality. This helps companies looking to commercialize their product significantly reduce their total operations cost, as well as speed time to market.
"The Total Peptide Management program is a manifestation of our larger mission. We want to help our customers in their effort to pioneer innovative drug discovery and development solutions for preserving and improving human life," said Takahiro Ogata, President & COO of American Peptide Company. "Moving forward in our mission, we will continue to demonstrate performance with integrity to deliver greater value to our customers, ensuring their ongoing success."
For more information on the Total Peptide Management program, stop by booth # 2913-B5 (California Pavilion) at the BIO International Convention, June 17 - 20, 2008, San Diego, CA,.
About American Peptide Company, Inc.
American Peptide Company is a leading manufacturer of peptides and peptide conjugates. The company offers comprehensive selection of pre-manufactured catalog peptides, custom synthesis, and GMP generic peptide active pharmaceutical ingredients (APIs). Its manufacturing facility in Sunnyvale, California, offers research Grade peptides to customers, and its Vista facility, also in California, provides GMP manufacturing and services. The company also offers a portfolio of value-added services, including process development, scale-up production, analytical and process validation, stability studies, CMC, DMF, and regulatory support.
American Peptide Company is experienced in solid-phase and solution-phase peptide synthesis, as well as organic conjugations, proteins and PEG. The company is a wholly-owned subsidiary of Itoham Foods, Inc., which is headquartered in Japan, with offices in the U.S. and presence in Japan, South Korea, and the UK. American Peptide Company remains dedicated to delivering high-quality peptides to pharmaceutical and biotech companies worldwide. For more information, please visit www.americanpeptide.com
.SOURCE: American Peptide Company, Inc.